Lynparza fails a PhIII test in colorectal cancer, cutting off big R&D avenue for Merck and AstraZeneca
As AstraZeneca and Merck look to continue building out their Lynparza franchise, one cancer type is proving too tough a nut to crack.
The Big Pharma partners reported Tuesday morning that a Phase III trial evaluating Lynparza in colorectal cancer as both a monotherapy and in combination with Avastin was stopped early due to futility. The move comes after the data monitoring committee reviewed data for a planned interim analysis. Both drug arms will be discontinued, the companies said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.